...
首页> 外文期刊>Vaccine >Toxoplasma gondii: Vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice
【24h】

Toxoplasma gondii: Vaccination with a DNA vaccine encoding T- and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice

机译:弓形虫:用编码SAG1,GRA2,GRA7和ROP16的T细胞和B细胞表位的DNA疫苗接种可预防小鼠的急性弓形虫病

获取原文
获取原文并翻译 | 示例

摘要

Toxoplasma gondii (T. gondii) is an obligate, intracellular, protozoan parasite that infects large variety of warm-blooded animals including humans, livestock, and marine mammals, and causes the disease toxoplasmosis. Although T. gondii infection rates differ significantly from country to country, it still has a high morbidity and mortality. In these circumstances, developing an effective vaccine against T. gondii is urgently needed for preventing and treating toxoplasmosis. The aim of this study was to construct a multi-epitopes DNA vaccine and evaluate the immune protective efficacy against acute toxoplasmosis in mice. Therefore, twelve T- and B-cell epitopes from SAG1, GRA2, GRA7 and ROP16 of T. gondii were predicted by bioinformatics analysis, and then a multi-epitopes DNA vaccine was constructed. Mice immunized with the multi-epitopes DNA vaccine gained higher levels of IgG titers and IgG2a subclass titers, significant production of gamma interferon (IFN-gamma), percentage of T lymphocyte subsets, and longer survival times against the acute infection of T. gondii compared with those of mice administered with empty plasmid and those in control groups. Furthermore, a genetic adjuvant pEGFP-RANTES (pRANTES) could enhance the efficacy of the multi-epitopes DNA vaccine associating with humoral and cellular (Th1, CD8(+) T cell) immune responses. Above all, the DNA vaccine and the genetic adjuvant revealed in this study might be new candidates for further vaccine development against T. gondii infection. (C) 2015 Elsevier Ltd. All rights reserved.
机译:弓形虫(T. gondii)是专性的,细胞内的原生动物寄生虫,可感染包括人类,牲畜和海洋哺乳动物在内的多种温血动物,并引起弓形虫病。尽管刚地弓形虫的感染率因国家而异,但其发病率和死亡率仍然很高。在这些情况下,迫切需要开发一种有效的抗弓形虫疫苗来预防和治疗弓形虫病。这项研究的目的是构建一种多表位的DNA疫苗,并评估对小鼠急性弓形虫病的免疫保护功效。因此,通过生物信息学分析预测了弓形虫SAG1,GRA2,GRA7和ROP16的十二个T细胞和B细胞表位,然后构建了多表位DNA疫苗。与多表位DNA疫苗免疫的小鼠相比,弓形虫的急性感染获得更高的IgG滴度和IgG2a亚类滴度水平,γ干扰素(IFN-γ)的大量产生,T淋巴细胞亚群的百分比以及更长的存活时间。给予空质粒的小鼠和对照组。此外,遗传佐剂pEGFP-RANTES(pRANTES)可以增强多表位DNA疫苗与体液和细胞(Th1,CD8(+)T细胞)免疫反应相关的功效。最重要的是,这项研究中揭示的DNA疫苗和遗传佐剂可能是针对弓形虫感染的进一步疫苗开发的新候选者。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号